Drug Trial Radar · NCT05266014
This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease
Last checked: Nov 19, 2026Latest source record: Apr 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Mar 12, 2021
Primary completion
Aug 15, 2023
Study completion Aug 15, 2023
Sponsor
- Lead sponsor
- RBP4 Pty LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Belite Bio, Inc
- First posted
- Mar 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Stargardt disease 1 (STGD1) is the most prevalent form of juvenile macular degeneration. It is caused by a rare, inherited autosomal recessive trait, leading to severe and irreversible blindness by the first or second decade of life. Earlier onset of the disease is related to a rapid vision loss, while patients with a later onset tend to have a better prognosis. This study will enrol subjects aged 12-18 years old with a confirmed clinical diagnosis of Stargardt disease type 1 (STGD1). This study will include 2 phases, the phase 1b portion is to determine the optimal dose for phase 2 based on the extent of retinol binding protein 4 (RBP4) reduction after 2 cycles of tinlarebant treatment. The phase 2 portion will evaluate the safety and efficacy of a single daily dose of tinlarebant over a 24-month treatment period.
Conditions
- Stargardt Disease
Interventions
tinlarebantDrug
Phase 1b Portion: tinlarebant will be self-administered orally once daily for 2 cycles, 14 days per cycle. Phase 2 portion: tinlarebant will be self-administered orally once daily for 24 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate systemic and ocular safety and tolerability of tinlarebant.Time frame: From baseline to 24 months
- The optimal dose for Phase 2.Time frame: Up to 24 months
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Sydney Children's Hospitals Network
Westmead, New South Wales, Australia
Lions Eye Institute
Perth, Western Australia, Australia
National Taiwan University Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.